Literature DB >> 12954149

Treatment of Gastrointestinal Problems in Cystic Fibrosis.

Maria R. Mascarenhas1.   

Abstract

The gastrointestinal (GI) manifestations of cystic fibrosis (CF) are varied and include pancreatic insufficiency, meconium ileus, distal intestinal obstruction syndrome (DIOS), liver disease, and other less common manifestations. Treatment of pancreatic insufficiency consists of providing appropriate pancreatic enzyme replacement therapy and may include raising duodenal pH to allow for optimal action of these enzymes. Despite a number of pancreatic enzyme replacement products, malabsorption cannot be normalized. Management of DIOS depends on the severity of the symptoms; adequate hydration is very important. Polyethylene glycol solutions are being increasingly used. The precipitating cause of the episode of DIOS should be looked for so future episodes can be prevented. Liver disease is relatively silent and annual monitoring of liver function and status is recommended. Treatment is mainly supportive and the role of ursodeoxycholic acid in the prevention of cirrhosis needs to be better defined. Nutritional status is an important part of management of all GI and liver manifestations of CF. A team approach and the assistance of a registered dietitian are extremely valuable in managing the GI and liver manifestations of CF.

Entities:  

Year:  2003        PMID: 12954149     DOI: 10.1007/s11938-003-0045-2

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  43 in total

Review 1.  Consensus report on nutrition for pediatric patients with cystic fibrosis.

Authors:  Drucy Borowitz; Robert D Baker; Virginia Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-09       Impact factor: 2.839

2.  Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres.

Authors:  J H Meyer; R Lake
Journal:  Pancreas       Date:  1997-10       Impact factor: 3.327

3.  Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension.

Authors:  D Debray; P Lykavieris; F Gauthier; B Dousset; A Sardet; A Munck; H Laselve; O Bernard
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

4.  Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition.

Authors:  C D Rudolph; L J Mazur; G S Liptak; R D Baker; J T Boyle; R B Colletti; W T Gerson; S L Werlin
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001       Impact factor: 2.839

5.  A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.

Authors:  R C Stern; J D Eisenberg; J S Wagener; R Ahrens; M Rock; G doPico; D M Orenstein
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

6.  The spectrum of appendiceal disease in cystic fibrosis.

Authors:  J P Coughlin; M W Gauderer; R C Stern; C F Doershuk; R J Izant; R M Zollinger
Journal:  J Pediatr Surg       Date:  1990-08       Impact factor: 2.545

7.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.

Authors:  C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

8.  High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.

Authors:  S C FitzSimmons; G A Burkhart; D Borowitz; R J Grand; T Hammerstrom; P R Durie; J D Lloyd-Still; A B Lowenfels
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

9.  Management and survival of meconium ileus. A 30-year review.

Authors:  C A Del Pin; C Czyrko; M M Ziegler; T F Scanlin; H C Bishop
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

10.  Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis.

Authors:  P R Durie; L Bell; W Linton; M L Corey; G G Forstner
Journal:  Gut       Date:  1980-09       Impact factor: 23.059

View more
  5 in total

1.  Lipid mapping of colonic mucosa by cluster TOF-SIMS imaging and multivariate analysis in cftr knockout mice.

Authors:  Marc Brulet; Alexandre Seyer; Aleksander Edelman; Alain Brunelle; Janine Fritsch; Mario Ollero; Olivier Laprévote
Journal:  J Lipid Res       Date:  2010-07-08       Impact factor: 5.922

2.  Potato crisps without pancreatic extracts supplements: a potential cause of the distal intestinal obstruction in cystic fibrosis.

Authors:  F Kopriva; K Michálková; M Zápalka; J Malý
Journal:  Eur J Pediatr       Date:  2006-11-24       Impact factor: 3.183

3.  Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice.

Authors:  Emily M Bradford; Maureen A Sartor; Lara R Gawenis; Lane L Clarke; Gary E Shull
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-22       Impact factor: 4.052

4.  Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10.

Authors:  Oxana Norkina; Robert C De Lisle
Journal:  BMC Genet       Date:  2005-05-27       Impact factor: 2.797

5.  Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma.

Authors:  Saqib Walayat; Nooreen Hussain; Jaymon Patel; Faiz Hussain; Preeti Patel; Sonu Dhillon; Bhagat Aulakh; Subramanyam Chittivelu
Journal:  Int Med Case Rep J       Date:  2017-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.